AbbVie strikes deal with Trump administration on drug prices, US investment

AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing

NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery

Aragen slashes drug development time with CHOMax platform

CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes

Teva and Royalty Pharma partner in $500 million deal to fast-track vitiligo treatment

Royalty Pharma to provide up to $500 million, including $75 million for Phase 2b funding

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment

CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration

FDA rejects Vanda’s jet lag drug in current form

Vanda strongly disputes the FDA’s reasoning

Alembic announces USFDA tentative approval for Bosutinib tablets

AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030

AstraZeneca appoints Laura Colon as new President of Spain

After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets

Newron secures key European patent for schizophrenia drug Evenamide

This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately